-
Earnings Scheduled For July 19
Tuesday, July 19, 2011 - 3:20am | 474Harley-Davidson Inc (NYSE: HOG) is projected to report its Q2 EPS at $0.71 on revenue of $1.26 billion. Yahoo! Inc (NASDAQ: YHOO) is projected to report its Q2 earnings at $0.18 per share on revenue of $1.11 billion. Bank of America Corporation (NYSE: BAC) is expected to post a Q2 loss at $0.90...
-
Sanofi-Aventis (SNY): Low-risk potential
Monday, July 18, 2011 - 8:00pm | 114by Paul Tracy, editor High-Yield International Paris-based pharmaceutical giant Sanofi-Aventis (SNY) is in the midst of a transformation. With the bulk of the major patent expirations now behind it, investors are beginning to focus on the firm's ability to deliver on growth drivers in the form of...
-
Nabi Pharmaceuticals Plunges On Phase III Data
Monday, July 18, 2011 - 5:34pm | 470Investors who own shares in Nabi Biopharamaceuticals were likely quite distraught this morning. The company opened today worth almost a full 4 dollars less than its closing value yesterday, down a staggering 66.43%. Nabi Biopharamaceuticals is a bio-pharama company which develops vaccines to...
-
Marina Biotech Announces Changes to Board of Directors
Monday, July 18, 2011 - 4:05pm | 212Marina Biotech, Inc. (NASDAQ: MRNA) today announced that R. John Fletcher was elected to the Company's Board of Directors effective July 14, 2011, replacing Board member Chiang Li, Ph.D., M.D., who announced his retirement from the Marina Biotech board prior to the 2011 annual meeting of...
-
Hearing Positive Twitter Chatter on Amarin; Possible Deal with Pfizer
Monday, July 18, 2011 - 3:21pm | 54@markflowchatter reports of a rumored deal between Amarin (NASDAQ: AMRN) and Pfizer (NYSE: PFE). Look for news coming out of a meeting the company has with Lazard tomorrow at Noon.
-
Johnson & Johnson Announces Third-Quarter 2011 Quarterly Dividend of $0.57/Share
Monday, July 18, 2011 - 2:56pm | 59Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2011 of $0.57 per share on the company's common stock. The dividend is payable on Sept. 13, 2011, to shareholders of record at the close of business on Aug. 30, 2011...
-
Eli Lilly & Earnings Preview: Analysts Predict Higher Earnings Over Prior Quarter
Monday, July 18, 2011 - 2:55pm | 560It's time to get ready for Eli Lilly & (NYSE: LLY) earnings! Don't be caught off-guard: The company releases its next round of earnings this Thursday, July 21, 2011. Wondering what to expect from this Thursday's announcement? Don't worry. Here's your essential guide to Eli Lilly &'s...
-
Lannett Receives FDA Approval for Diethylproprion HCl Tablets, 25 mg
Monday, July 18, 2011 - 1:28pm | 100Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application of Diethylproprion HCl Tablets, 25 mg. Diethylproprion HCl Tablets, 25 mg, is therapeutically equivalent to the reference listed drug,...
-
Monday's Put/Call Ratio Leaders Leaders
Monday, July 18, 2011 - 12:28pm | 78Here are today's Put/Call Ratio Leaders leaders… 1. Robert Half International (NYSE: RHI) 6,006 puts, 1 call 2. Solarwinds (NYSE: SWI) 5,230 puts, 4 calls 3. Vimpel Communications (NYSE: VIP) 16,262 puts, 23 calls 4. Cadence Pharmaceuticals (NASDAQ: CADX) 4,027 puts, 20 calls 5. FMC Technologies...
-
Merck Announces VICTRELIS First-in-Class Oral Hepatitis C Virus Protease Inhibitor, Approved in the EU for Treatment of Chronic Hepatitis C
Monday, July 18, 2011 - 11:32am | 75Merck (NYSE: MRK) today announced that the European Commission has approved VICTRELISTM (boceprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or...
-
Optimer Launches DIFICID Tablets for Treatment of Clostridium Difficile-Associated Diarrhea in Patients 18 Years of Age and Older
Monday, July 18, 2011 - 11:31am | 156Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the commercial launch of DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea in patients 18 years of age and older. In two large Phase 3 clinical studies, DIFICID had clinical response rates at...
-
Top Performing Industries For July 18
Monday, July 18, 2011 - 10:13am | 174At 10:10 am, the Dow fell 1.17% to 12,333.96, the broader Standard & Poor's 500 index moved down 0.99% to 1,303.08 and the NASDAQ composite index dropped 1.05% to 2,760.50. The industries that are still afloat in the market today are: Silver: This industry jumped 2.29% by 10:10 am. The top...
-
Duncan Williams Maintains Buy on Forest Laboratories
Monday, July 18, 2011 - 9:56am | 133Duncan Williams is out with its report today on Forest Laboratories (NYSE: FRX), maintaining Buy. In a note to clients, Duncan Williams writes, "(1) We think the marketed portfolio is worth $28 per share and conservatively allocate $7 to the pipeline, with $10/share in cash. (2) The company has an...
-
Deutsche Bank Reiterates Buy on Valeant Pharmaceuticals, Raises PT to $64
Monday, July 18, 2011 - 9:26am | 56Deutsche Bank reiterated its Buy rating on Valeant Pharmaceuticals (NYSE: VRX). At the same time, the rating agency raised its price target on the company's stock from $62 to $64. On Friday, VRX closed the day at $55. Its shares added 0.29% to their value in today's pre-market trading to stand...
-
Piper Jaffray Reiterates Overweight on Valeant Pharmaceuticals
Monday, July 18, 2011 - 8:57am | 84Piper Jaffray is out with its report today on Valeant Pharmaceuticals (NYSE: VRX), reiterating Overweight. In a note to clients, Piper Jaffray writes, "With strong cash flows, plus additional M&A activity, we believe VRX is attractive. Our $65 PT is based on our 2014 EPS of $4.71 (down from $4...